NVA237 BID Versus Placebo Twelve-week Efficacy Study

NCT01715298 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

432

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: NVA237
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals